Rukayat Olayemi Oni designed a 20-question ONCODIAX™ diagnostic assessment to help molecular laboratories and diagnostic organizations evaluate their operational maturity across the four strategic pillars.
Each question identifies potential weaknesses involving molecular diagnostic intelligence, biomarker and assay reliability, laboratory workflow, and diagnostic-performance measurement.
Across cancer diagnostic laboratories and oncology testing environments, increasingly sophisticated molecular technologies are being used to detect cancer-associated signals, characterize molecular abnormalities, monitor disease progression, and support precision treatment decisions.
These environments generate complex information involving genomic alterations, circulating tumor DNA (ctDNA), methylation patterns, protein biomarkers, molecular assay signals, specimen characteristics, analytical controls, instrument performance, and quality indicators.
Yet the availability of advanced molecular technologies does not automatically produce reliable or clinically actionable diagnostic intelligence. Laboratories must continuously manage pre-analytical specimen variability, assay sensitivity, molecular signal quality, analytical reproducibility, quality-control deviations, instrument performance, workflow complexity, turnaround requirements, and regulatory standards.
ONCODIAX™ was developed to address these systemic gaps by integrating molecular diagnostic intelligence, biomarker and assay reliability assessment, laboratory workflow optimization, and diagnostic-performance measurement into one cohesive Precision Molecular Oncology Diagnostics framework.
ONCODIAX™ (Oncology Molecular Diagnostic Intelligence & Optimization Framework) integrates molecular diagnostic intelligence, biomarker and assay reliability, laboratory workflow optimization, and diagnostic-performance intelligence into one structured architecture — a modular, technology-adaptive, and laboratory-responsive framework capable of operating alongside existing LIMS, molecular diagnostic platforms, quality-management systems, laboratory SOPs, assay-validation procedures, and clinical laboratory workflows.
MDII™ — evaluates specimen quality, pre-analytical variability, and testing readiness.
BARS™ — identifies emerging reliability risks before they affect diagnostic performance.
MWOM™ — identifies operational bottlenecks across the diagnostic pathway.
DPRI™ — connects laboratory activities with measurable analytical outcomes.
Your responses will reveal your organization's Molecular Diagnostic Readiness and its capacity to transform specimen, biomarker, assay, quality-control, workflow, and laboratory-performance information into reliable and efficient molecular oncology diagnostics — scored across the framework's A.P.O.I. model: Assessment Intelligence, Predictive Reliability, Operational Optimization, and Improvement Intelligence.
ONCODIAX™